ExpreS2ion Biotech aktie (EXPRS2) | Pressmeddelande - Börskollen
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

•Investeringsmöjlighet: Bli delägare i global ledare inom AI-baserad videoanalys på säkerhetsmarknaden (annons)

Pressmeddelanden från ExpreS2ion Biotech

 Bevaka pressreleaser
Kurs från TradingView
StartNyheterPressreleaserRiktkurserInsynshandelBlankningAnalyserBloggarVideosPodcasts

ExpreS2ion Biotechnologies: Full commitments from members of ExpreS2ion's Board and Management holding warrants of series TO 10

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS...

Cision • Igår 08:45

ExpreS2ion Biotechnologies: ExpreS2ion announces the start of the exercise period for warrants of series TO 10

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS...

Cision • I förrgår 08:30

ExpreS2ion to present in upcoming investor and scientific events

Hørsholm, Denmark, 18 November 2024 – ExpreS2ion Biotech Holding AB’s subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will particip...

Cision • 18 Nov 11:00

ExpreS2ion announces TO 10 warrant exercise price and start of exercise period

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS...

Cision • 14 Nov 19:47

Correction: ExpreS2ion announces financial results for the third quarter of 2024

Hørsholm, Denmark, 14 November 2024 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its third quarter and year-to-date financ...

Cision • 14 Nov 08:53

ExpreS2ion announces financial results for the third quarter of 2024

Hørsholm, Denmark, 14 November 2024 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its third quarter and year-to-date financ...

Cision • 14 Nov 08:30

ExpreS2ion and Evaxion announce positive preclinical data for cytomegalovirus (CMV) vaccine program ES2B-I002

Hørsholm, Denmark, 12 November 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion"), a clinical-st...

Cision • 12 Nov 14:00

ExpreS2ion CEO talks to BioStock about partnering efforts at BIO-Europe

Heading towards phase I studies with breast cancer vaccine candidate ES2B-C001, ExpreS2ion Biotech is actively looking for partners.

Cision • 05 Nov 15:21

ExpreS2ion CEO talking to BioStock about partnering efforts at BIO-Europe

Heading towards phase I studies with breast cancer vaccine candidate ES2B-C001, ExpreS2ion Biotech is actively looking for partners.

Cision • 05 Nov 08:15

ExpreS2ion Biotech presenterar på BioStock Life Science Summit 21 november

Den sjunde upplagan av BioStock Life Science Summit går av stapeln 20-21 november, i Lund.

Cision • 04 Nov 11:00

ExpreS2ion Biotech will present at the BioStock Life Science Summit, November 21

The seventh edition of the BioStock Life Science Summit will take place in Lund on November 20-21.

Cision • 04 Nov 11:00

ExpreS2ion to present in upcoming investor and scientific events

Hørsholm, Denmark, 31 October2024 – ExpreS2ion Biotech Holding AB’s subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participat...

Cision • 31 Oct 12:00

The Board of Directors of ExpreS2ion Biotech Holding AB (publ) has resolved on the record date for the reverse share split

Hørsholm, Denmark, 24 October 2024 - At the Extraordinary General Meeting of ExpreS2ion Biotech Holding AB (publ) ("ExpreS2ion" or the "Comp...

Cision • 24 Oct 12:00

Bulletin from the Extraordinary General Meeting of ExpreS2ion Biotech Holding AB (publ)

Today, on 21 October 2024, ExpreS2ion Biotech Holding AB ("ExpreS2ion" or the "Company") has held an Extraordinary General Meeting 2024 (the...

Cision • 21 Oct 11:00

ExpreS2ion and Serum Institute of India have entered in a term sheet regarding proposed development and commercialisation of novel malaria vaccines

Hørsholm, Denmark, 16 October 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion"), a clinical-sta...

Cision • 16 Oct 13:17

Notice to attend the Extraordinary General Meeting in ExpreS2ion Biotech Holding AB (publ)

N.B. This notice has been prepared in both Swedish and English language versions.

Cision • 19 Sep 09:15

Kallelse till extra bolagsstämma i ExpreS2ion Biotech Holding AB (publ)

Aktieägarna i ExpreS2ion Biotech Holding AB (publ), org.

Cision • 19 Sep 09:15

ExpreS2ion to present in upcoming investor events

Hørsholm, Denmark, 10 September 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will particip...

Cision • 10 Sep 14:00

ExpreS2ion announces publication of sponsored research reports

Hørsholm, Denmark, 23 August 2024 – ExpreS2ion Biotech Holding AB (Nasdaq First North Growth Market: EXPRS2) is pleased to announce the publ...

Cision • 23 Aug 12:45

ExpreS2ion announces financial results for the second quarter of 2024

Hørsholm, Denmark, 15 August 2024 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its second quarter and half-year financial ...

Cision • 15 Aug 08:30

ExpreS2ion submits Clinical Trial Application (CTA) to conduct Phase I study of ES2B-C001, an innovative therapeutic breast cancer vaccine

Hørsholm, Denmark, 06 August 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion"), a clinical-stag...

Cision • 06 Aug 16:18

ExpreS2ion resolves on a directed issue of units to guarantors in connection with the completed rights issue

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA,...

Cision • 05 Jul 13:06

ExpreS2ion announces U.S. patent issue notification for glyco-engineered immunization antigens

Hørsholm, Denmark, 3 July 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") a late preclinical ...

Cision • 03 Jul 12:30

ExpreS2ion announces final outcome of its rights issue

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA,...

Cision • 01 Jul 13:20

Rights issue subscription period ending 27 June 2024; subscription possible via form

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA,...

Cision • 26 Jun 09:00

ExpreS2ion announces poster presentation on the use of glycoengineered Drosophila S2 cells for production of highly immunogenic antigens at the ESACT meeting

Hørsholm, Denmark, 24 June 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") today announces th...

Cision • 24 Jun 15:00

Publication of clinical Phase Ib trial data for the adjuvanted RH5.1 blood-stage malaria vaccine

Hørsholm, Denmark, 21 June 2024 – ExpreS[2]ion Biotech Holding AB’s affiliate ExpreS[2]ion Biotechnologies ApS (“ExpreS2ion") announces the ...

Cision • 21 Jun 11:30

ExpreS2ion hosts informative webinar on 2024 Rights Issue and Highlights Key Updates on HER2+ Breast Cancer Vaccine

Hørsholm, Denmark, 18 June 2024 – ExpreS2ion Biotech Holding AB’s ("ExpreS2ion" or the "Company") (NASDAQ First North: EXPRS2) announces tha...

Cision • 18 Jun 13:00

BioStock: Rights issue takes Expres2ion breast cancer vaccine to phase I

Having validated its vaccine platform in Covid-19, Expres2ion Biotech now turns to the treatment of breast cancer.

Cision • 14 Jun 08:45

ExpreS2ion CEO to BioStock: “Compelling preclinical package gives us confidence”

Based on its proprietary protein expression platform, ExpreS2ion Biotech advances its ES2B-C001 breast cancer vaccine candidate toward clini...

Cision • 12 Jun 09:15

The subscription period in ExpreS2ion’s rights issue begins today

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA,...

Cision • 12 Jun 08:45

ExpreS2ion to present in upcoming investor and scientific events

Hørsholm, Denmark, 10 June 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate i...

Cision • 10 Jun 14:00

ExpreS2ion publishes prospectus in connection with its rights issue of units

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA,...

Cision • 05 Jun 16:40

Bulletin from the Annual General Meeting of ExpreS2ion Biotech Holding AB held on 5 June 2024

The Annual General Meeting 2024 (the "AGM") of ExpreS2ion Biotech Holding AB ("ExpreS2ion" or the "Company") was held today on 5 June 2024.

Cision • 05 Jun 11:30

ExpreS2ion announces financial results for the first quarter of 2024

Hørsholm, Denmark, 16 May 2024 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its first quarter financial results for 2024.

Cision • 16 May 08:30

ExpreS2ion to present in spring investor events

Hørsholm, Denmark, 15 May 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate in...

Cision • 15 May 15:17

ExpreS2ion annual report for 2023 published

Hørsholm, Denmark, 8 May 2024 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that the company's annual report for the finan...

Cision • 08 May 12:05

Notice to attend the Annual General Meeting in ExpreS2ion Biotech Holding AB (publ)

N.B. This notice has been prepared in both Swedish and English language versions.

Cision • 03 May 10:30

Kallelse till årsstämma i ExpreS2ion Biotech Holding AB (publ)

Aktieägarna i ExpreS2ion Biotech Holding AB (publ), org.

Cision • 03 May 10:30

ExpreS2ion announces a rights issue of units of approximately SEK 60 million

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA,...

Cision • 02 May 21:23

ExpreS2ion to receive approximately SEK 22.5 million dividend payment from AdaptVac ApS

Hørsholm, Denmark, 23 April 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") today announced t...

Cision • 23 Apr 14:20

ExpreS2ion changes dates for the annual general meeting and the publication of the annual report for 2023

Hørsholm, Denmark, 16 April 2024 – ExpreS2ion Biotech Holding AB ("ExpreS2ion" or the "Company") announces that the Board of Directors of Ex...

Cision • 16 Apr 16:40

ExpreS2ion announces completion of GLP safety study for ES2B-C001 (HER2-VLP) breast cancer vaccine candidate

Hørsholm, Denmark, 16 April 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") is pleased to ann...

Cision • 16 Apr 14:29

ExpreS2ion to present in investor and R&D events in March

Hørsholm, Denmark, 15 April 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate ...

Cision • 15 Apr 15:00

ExpreS2ion to present in investor and R&D events in March

Hørsholm, Denmark, 29 February 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participa...

Cision • 29 Feb 13:30

ExpreS2ion’s Associated Company AdaptVac Receives Milestone Payment Following Completion of Bavarian Nordic’s Clinical Phase III Study for the COVID-19 Vaccine

Hørsholm, Denmark, 21 February 2024 – ExpreS[2]ion Biotech Holding AB’s affiliate ExpreS[2]ion Biotechnologies ApS (“ExpreS2ion") today anno...

Cision • 21 Feb 09:00

ExpreS2ion announces financial results for the fourth quarter and full-year 2023

Hørsholm, Denmark, 8 February 2024 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its fourth quarter and full-year financial...

Cision • 08 Feb 08:30

ExpreS2ion to present in Redeye Fight Cancer event and the Bio Innovation Leaders Summit

Hørsholm, Denmark, 22 January 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participat...

Cision • 22 Jan 14:30

ExpreS2ion to present new Nipah virus vaccine project in upcoming webcast

Hørsholm, Denmark, 12 December 2023 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will provide a...

Cision • 12 Dec 2023 10:30

Pareto Securities publishes research report

Hørsholm, Denmark, 4 December 2023 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that ...

Cision • 04 Dec 2023 09:01

ExpreS2ion announces new EU-funded Horizon Europe grant award for Nipah virus vaccine development

Hørsholm, Denmark, 1 December 2023 – ExpreS[2]ion Biotech Holding AB’s affiliate ExpreS[2]ion Biotechnologies ApS (“ExpreS2ion") today annou...

Cision • 01 Dec 2023 08:40

ExpreS2ion CEO interviewed, CFO provides update at life science investor conference, Analysguiden publishes research report

Hørsholm, Denmark, 27 November 2023 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that...

Cision • 27 Nov 2023 13:30

ExpreS2ion announces financial results for the third quarter 2023

Hørsholm, Denmark, 16 November 2023– ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its third quarter financial results for 20...

Cision • 16 Nov 2023 08:30

ExpreS2ion Biotechnologies: Bulletin from the Extraordinary General Meeting of ExpreS2ion Biotech Holding AB held on 9 November 2023

Helsingborg, Sweden, 9 November 2023 - The extraordinary general meeting ("EGM") of ExpreS2ion Biotech Holding AB ("ExpreS2ion" or the "Comp...

Cision • 09 Nov 2023 11:00

ExpreS2ion to participate in upcoming events

Hørsholm, Denmark, 3 November 2023 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participat...

Cision • 03 Nov 2023 15:30

Background and rationale for the proposed incentive program 2023/2026

Hørsholm, Denmark, 25 October 2023 - With reference to Notice of Extraordinary General Meeting in ExpreS2ion Biotech Holding AB (Press relea...

Cision • 25 Oct 2023 18:10

Notice of Extraordinary General Meeting in ExpreS2ion Biotech Holding AB

N.B. This notice has been prepared in both Swedish and English language versions.

Cision • 23 Oct 2023 14:30

Kallelse till extra bolagsstämma i ExpreS2ion Biotech Holding AB

Aktieägarna i ExpreS2ion Biotech Holding AB, org.nr 559033-3729 ("Bolaget"), kallas härmed till extra bolagsstämma den 9 november 2023 klock...

Cision • 23 Oct 2023 14:30

ExpreS2ion to participate in upcoming events

Hørsholm, Denmark, 12 October 2023 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participat...

Cision • 12 Oct 2023 15:30

ExpreS2ion announces changes to leadership team

Hørsholm, Denmark, 27 September 2023 - ExpreS2ion Biotech Holding AB (“ExpreS2ion” or the “Company”), a pioneer in the development of innova...

Cision • 27 Sep 2023 17:15

Warrants of series TO 8 were exercised to approximately 18.5 percent and ExpreS2ion receives approximately SEK 3.4 million

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA,...

Cision • 25 Sep 2023 11:38

Last day of trading in warrants of series TO 8 in Expres2ion Biotechnologies is today, 18 September 2023

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA,...

Cision • 18 Sep 2023 08:30

ExpreS2ion’s Board, CEO and CFO commit to full exercise of their series TO 8 warrants

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA,...

Cision • 13 Sep 2023 09:00

ExpreS2ion announces the start of the exercise period for warrants of series TO 8

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA,...

Cision • 07 Sep 2023 08:30

ExpreS2ion publishes video presentation

Hørsholm, Denmark, 05 September 2023 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces tha...

Cision • 05 Sep 2023 14:30

ExpreS2ion announces TO 8 warrant exercise price and start of exercise period

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA,...

Cision • 04 Sep 2023 08:30

Phase III secondary endpoint data announced for the COVID-19 booster vaccine candidate

Hørsholm, Denmark, 31 August 2023 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") today provides a...

Cision • 31 Aug 2023 17:28

Correction: ExpreS2ion announces financial results for the second quarter 2023

Hørsholm, Denmark, 17 August 2023– ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its second quarter financial results for 202...

Cision • 17 Aug 2023 09:30

ExpreS2ion announces financial results for the second quarter 2023

Hørsholm, Denmark, 17 August 2023– ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its second quarter financial results for 202...

Cision • 17 Aug 2023 09:00

ExpreS2ion evaluates strategic options for its breast cancer vaccine candidate

Hørsholm, Denmark, 17 August 2023 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") today announces ...

Cision • 17 Aug 2023 08:58

Phase III topline results announced for the COVID-19 booster vaccine candidate

Hørsholm, Denmark, 27 June 2023 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") today provides an ...

Cision • 27 Jun 2023 14:58

12-month durability data announced for ABNCoV2 Phase II clinical trial

Hørsholm, Denmark, 16 June 2023 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") today provides an ...

Cision • 16 Jun 2023 09:30

ExpreS2ion to participate in upcoming events

Hørsholm, Denmark, 1 June 2023 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate an...

Cision • 01 Jun 2023 12:00

Bulletin from the Annual General Meeting of ExpreS2ion Biotech Holding AB held on 24 May 2023

Helsingborg, Sweden, 24 May 2023 – The annual general meeting 2023 ("AGM") of ExpreS2ion Biotech Holding AB ("ExpreS2ion" or the "Company") ...

Cision • 24 May 2023 11:00

ExpreS2ion announces financial results for the first quarter 2023

Hørsholm, Denmark, 16 May 2023– ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its first quarter financial results for 2023.

Cision • 16 May 2023 08:30

ExpreS2ion - Annual report for 2022 published

Hørsholm, Denmark, 2 May 2023 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that the company's annual report for the finan...

Cision • 02 May 2023 13:35

Notice to Annual General Meeting in ExpreS2ion Biotech Holding AB

N.B. This notice has been prepared in both Swedish and English language versions.

Cision • 24 Apr 2023 11:59

Kallelse till årsstämma i ExpreS2ion Biotech Holding AB

Aktieägarna i ExpreS2ion Biotech Holding AB, org.nr 559033-3729 ("Bolaget"), kallas härmed till årsstämma den 24 maj 2023 klockan 10.

Cision • 24 Apr 2023 11:59

ExpreS2ion resolves on a directed issue of units to guarantors in connection with the completed rights issue

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA,...

Cision • 21 Apr 2023 13:00

ExpreS2ion announces poster presentation on ES2B-C001 at the AACR Annual Meeting 2023

Hørsholm, Denmark, 18 April 2023 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") today announces t...

Cision • 18 Apr 2023 20:51

ExpreS2ion announces final outcome of its rights issue

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA,...

Cision • 14 Apr 2023 20:05

Rights issue subscription period ending 12 April 2023; subscription possible via form

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA,...

Cision • 11 Apr 2023 12:15

ExpreS2ion publishes video presentation

Hørsholm, Denmark, 11 April 2023 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that a ...

Cision • 11 Apr 2023 11:00

BioStock: ExpreS2ion CEO comments ongoing rights issue

ExpreS2ion Biotechnologies has a broad portfolio of vaccine candidates based on its ExpreS2 platform.

Cision • 05 Apr 2023 08:45

BioStock Investor Pitch: ExpreS2ion Biotechnologies

Danish ExpreS2ion Biotechnologies develops a portfolio of vaccines currently targeting Covid-19, breast cancer, influenza, malaria and, with...

Cision • 03 Apr 2023 08:00

BioStock: Multiple near-term milestones for ExpreS2ion Biotech

With an upcoming phase III readout and ongoing toxicology studies it is safe to say that ExpreS2ion Biotech has an interesting year ahead.

Cision • 31 Mar 2023 08:45

BioStock: ExpreS2ion´s CEO on current development and the rights issue

ExpreS2ion Biotechnologies is eagerly awaiting top-line results from the phase III study with its Covid-19 vaccine.

Cision • 29 Mar 2023 08:45

ExpreS2ion to participate in upcoming events

Hørsholm, Denmark, 27 March 2023 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate ...

Cision • 28 Mar 2023 11:00

ExpreS2ion publishes prospectus in connection with its rights issue of units

Hørsholm, Denmark, 27 March 2023 – On 3 March 2023, the Board of Directors of Expres2ion Biotech Holding AB (“ExpreS2ion” or the “Company”) ...

Cision • 27 Mar 2023 11:31

Bulletin from ExpreS2ion's extraordinary general meeting on 23 March 2023

Helsingborg, Sweden, 23 March 2023 – ExpreS2ion Biotech Holding AB's (“ExpreS2ion” or the “Company”) extraordinary general meeting took plac...

Cision • 23 Mar 2023 11:00

Pareto and Analysguiden publish research reports

Hørsholm, Denmark, 16 March 2023 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that Pa...

Cision • 16 Mar 2023 18:00

ExpreS2ion announces formation of Infectious Diseases Scientific Advisory Board

Hørsholm, Denmark, March 9, 2023 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") today announces t...

Cision • 09 Mar 2023 09:00

Notice to Extraordinary General Meeting in ExpreS2ion Biotech Holding AB

N.B. This notice has been prepared in both Swedish and English language versions.

Cision • 03 Mar 2023 20:53

Kallelse till extra bolagsstämma i ExpreS2ion Biotech Holding AB

Aktieägarna i ExpreS[2]ion Biotech Holding AB kallas härmed till extra bolagsstämma att hållas den 23 mars 2023 klockan 10:00, på Mindpark, ...

Cision • 03 Mar 2023 20:53

ExpreS2ion announces a rights issue of units of approximately SEK 102.4 million

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA,...

Cision • 03 Mar 2023 20:17

ExpreS2ion announces grant award for the development of new platforms for universal mucosal vaccines

Hørsholm, Denmark, March 3, 2023 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that th...

Cision • 03 Mar 2023 13:00

ExpreS2ion provides update on ABNCoV2 Phase III clinical trial

Hørsholm, Denmark, February 15, 2023– ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") today provides...

Cision • 15 Feb 2023 07:51

ExpreS2ion will present fourth quarter and full-year 2022 results

Hørsholm, Denmark, February 13, 2023 – ExpreS2ion Biotech Holding AB (“ExpreS2ion") is pleased to announce that it will present fourth quart...

Cision • 13 Feb 2023 16:46

ExpreS2ion announces financial results for the fourth quarter and full-year 2022

Hørsholm, Denmark, February 9, 2023– ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its fourth quarter and full-year financial...

Cision • 09 Feb 2023 08:30

Scientific article published about the Phase I clinical trial of the COVID-19 vaccine ABNCoV2

Hørsholm, Denmark, January 20, 2023 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that...

Cision • 20 Jan 2023 14:19